University of Texas's Southwestern Medical Center: Tackling Resistance To HIF2 Drugs With An RNA-Based Therapy
October 04, 2022
October 04, 2022
DALLAS, Texas, Oct. 4 (TNSres) -- The University of Texas's Southwestern Medical Center issued the following news release on Oct. 3, 2022:
Expected to be diagnosed in 2% of men and 1% of women in the U.S., kidney cancer has traditionally been one of the most challenging cancers to treat. Until 2005, only one drug had been approved by the Food and Drug Administration (FDA) to treat kidney cancer, which is resistant to both chemotherapy and conventional radiation. Since then, dis . . .
Expected to be diagnosed in 2% of men and 1% of women in the U.S., kidney cancer has traditionally been one of the most challenging cancers to treat. Until 2005, only one drug had been approved by the Food and Drug Administration (FDA) to treat kidney cancer, which is resistant to both chemotherapy and conventional radiation. Since then, dis . . .